Nuvation Bio Class A (NUVB) closed at $4.06 on November 12, 2026, down 5.4% from the previous close, on volume of 5,097,921 shares (30-day average 5,342,432).
Data as of November 12, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 6, 2026 | Calendar Put Spread | 18-Dec-26 : 17-Jun-27 5 P | 600 |
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 11, 2026. See the 10 largest for 30, 60 and 90 days
Nuvation Bio to Present at the Jefferies Global Healthcare Conference in London
PRNewswire (Tue, 10-Nov 4:05 PM ET)
Nuvation Bio Reports Third Quarter 2026 Financial Results and Provides Business Update
PRNewswire (Wed, 4-Nov 4:05 PM ET)
PRNewswire (Mon, 2-Nov 8:00 AM ET)
PRNewswire (Thu, 29-Oct 8:00 AM ET)
PRNewswire (Wed, 21-Oct 4:06 PM ET)
NUVB Wins FDA Label Update for IBTROZI Highlighting 49.70-Month Median Response Duration
Market Chameleon (Thu, 17-Sep 3:54 AM ET)
PRNewswire (Thu, 17-Sep 7:30 AM ET)
PRNewswire (Tue, 15-Sep 8:00 AM ET)
Nuvation Bio to Participate in Upcoming Investor Conferences
PRNewswire (Wed, 2-Sep 4:06 PM ET)
Nuvation Bio Granted FDA Fast Track Designation for Safusidenib for Treatment of IDH1-Mutant Glioma
PRNewswire (Thu, 20-Aug 8:00 AM ET)
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.
Nuvation Bio Class A trades on the NYSE stock market under the symbol NUVB.
As of November 12, 2026, NUVB stock price declined to $4.06 with 5,097,921 million shares trading.
NUVB has a beta of 1.40, meaning it tends to be more sensitive to market movements. NUVB has a correlation of 0.05 to the broad based SPY ETF.
NUVB has a market cap of $1.43 billion. This is considered a Small Cap stock.
Last quarter Nuvation Bio Class A reported $45 million in Revenue and -$.12 earnings per share. This beat revenue expectation by $11 million and missed earnings estimates by -$.02.
In the last 3 years, NUVB traded as high as $9.75 and as low as $1.21.
The top ETF exchange traded funds that NUVB belongs to (by Net Assets): VTI, IWM, VXF, IWO, IBB.
NUVB has underperformed the market in the last year with a price return of -18.5% while the SPY ETF gained +12.0%. NUVB has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -36.3% and -11.5%, respectively, while the SPY returned -1.5% and -2.0%, respectively.
NUVB support price is $4.14 and resistance is $4.45 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NUVB shares will trade within this expected range on the day.
